Expert corrective action

By mdi Consultants

Manufacturers are running afoul of the US FDA’s Corrective and Preventive Action requirements, resulting in official warning letters that delay market launches. Alan Schwartz, executive vice-president of mdi Consultants, explains how third-party consultation can smooth the process.

Enter your details below to view the free white paper

By downloading this White Paper, you acknowledge that may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how Business Trade Media International Limited may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.